Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BEBT-908 alone or with BEBT-209 plus endocrine therapy in HR-positive/HER2-negative advanced breast cancer after CDK4/6 inhibitor progression
ChiCTR2100054270Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifupinostat and bebt-209 in breast cancer (5 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Objective response rate, Pharmacokinetics and 7 more. Started Dec 2021; status: recruiting.
02
Drugs
ifupinostatbebt-209
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054270.